What is Adial Pharmaceuticals Inc's earnings per share (EPS)?

Adial Pharmaceuticals Inc (ADIL) reported diluted earnings per share of $-11.93 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Adial Pharmaceuticals Inc Financials

ADIL

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Adial Pharmaceuticals Inc (ADIL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Adial Pharmaceuticals Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.81x

For every $1 of reported earnings, Adial Pharmaceuticals Inc generates $0.81 in operating cash flow (-$6.5M OCF vs -$8.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$8.0M

YoY+39.6%

Adial Pharmaceuticals Inc reported -$8.0M in net income in fiscal year 2025. This represents an increase of 39.6% from the prior year.

EPS (Diluted)

$-11.93

Adial Pharmaceuticals Inc earned $-11.93 per diluted share (EPS) in fiscal year 2025. This represents an increase of 82.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5.9M

YoY+56.8%

5Y CAGR+6.0%

Adial Pharmaceuticals Inc held $5.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Adial Pharmaceuticals Inc had 1M shares outstanding in fiscal year 2025. This represents an increase of 329.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-151.2%

YoY+173.2pp

5Y CAGR+122.1pp

Adial Pharmaceuticals Inc's ROE was -151.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 173.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.6M

YoY-18.9%

5Y CAGR-14.9%

Adial Pharmaceuticals Inc invested $2.6M in research and development in fiscal year 2025. This represents a decrease of 18.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ADIL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.6M-18.9%	$3.2M+154.9%	$1.3M-35.0%	$2.0M-76.8%	$8.4M+43.4%	$5.9M
SG&A Expenses	$5.2M+2.5%	$5.1M-10.1%	$5.6M-36.9%	$8.9M-4.7%	$9.3M+84.1%	$5.1M
Operating Income	-$7.8M+5.9%	-$8.3M-20.3%	-$6.9M+36.6%	-$10.9M+43.7%	-$19.3M-76.5%	-$10.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	-$502+99.5%	-$94K	N/A
Net Income	-$8.0M+39.6%	-$13.2M-157.6%	-$5.1M+59.8%	-$12.7M+34.5%	-$19.4M-78.3%	-$10.9M
EPS (Diluted)	$-11.93	$-68.01	$-3.60+71.7%	$-12.71	$-1.04	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$521K-28.8%	$732K-2.0%	$747K	N/A	$1.0M+1.9%	$1.0M+122.9%	$454K
SG&A Expenses	N/A	$1.2M+8.1%	$1.2M-24.3%	$1.5M	N/A	$1.2M-7.4%	$1.3M-8.3%	$1.4M
Operating Income	N/A	-$1.8M+6.3%	-$1.9M+17.0%	-$2.3M	N/A	-$2.2M+3.3%	-$2.3M-24.0%	-$1.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$1.8M+8.4%	-$2.0M+12.1%	-$2.2M	N/A	-$2.2M+10.8%	-$2.5M+62.0%	-$6.5M
EPS (Diluted)	N/A	$-0.08+55.6%	$-0.18	$-0.34	N/A	$-0.38+35.6%	$-0.59+73.1%	$-2.19

ADIL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$6.7M+32.3%	$5.0M+6.5%	$4.7M-17.4%	$5.7M-23.3%	$7.5M+36.1%	$5.5M
Current Assets	$6.2M+52.3%	$4.1M+26.9%	$3.2M-33.1%	$4.8M-26.0%	$6.5M+25.8%	$5.1M
Cash & Equivalents	$5.9M+56.8%	$3.8M+32.7%	$2.8M-29.4%	$4.0M-34.0%	$6.1M+37.7%	$4.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$249K0.0%	$249K	N/A
Total Liabilities	$1.4M+43.1%	$976K+49.4%	$653K-73.4%	$2.5M-38.1%	$4.0M+163.5%	$1.5M
Current Liabilities	$1.4M+43.1%	$976K+49.4%	$653K-63.5%	$1.8M-34.2%	$2.7M+80.8%	$1.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.3M+29.7%	$4.1M-0.4%	$4.1M+24.6%	$3.3M-6.6%	$3.5M-12.0%	$4.0M
Retained Earnings	-$90.0M-9.7%	-$82.0M-19.2%	-$68.8M-8.0%	-$63.7M-25.0%	-$50.9M-61.6%	-$31.5M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$6.7M+17.9%	$5.7M-16.8%	$6.8M+97.1%	$3.5M-31.6%	$5.0M-24.9%	$6.7M+35.6%	$4.9M	N/A
Current Assets	$6.2M+23.3%	$5.0M-17.5%	$6.1M+131.2%	$2.6M-35.2%	$4.1M-27.8%	$5.6M+47.0%	$3.8M	N/A
Cash & Equivalents	$5.9M+27.7%	$4.6M-22.1%	$5.9M+150.0%	$2.4M-36.9%	$3.8M-27.9%	$5.2M+58.3%	$3.3M-34.6%	$5.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M+21.0%	$1.2M-4.6%	$1.2M-8.6%	$1.3M+35.7%	$976K+17.7%	$829K+23.4%	$672K	N/A
Current Liabilities	$1.4M+21.0%	$1.2M-4.6%	$1.2M-8.6%	$1.3M+35.7%	$976K+17.7%	$829K+23.4%	$672K	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.3M+17.1%	$4.5M-19.4%	$5.6M+162.9%	$2.1M-47.7%	$4.1M-30.9%	$5.9M+37.6%	$4.3M-30.1%	$6.1M
Retained Earnings	-$90.0M-2.3%	-$88.0M-2.1%	-$86.2M-2.3%	-$84.2M-2.7%	-$82.0M-2.6%	-$79.9M-2.8%	-$77.7M	N/A

ADIL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.5M+6.2%	-$6.9M-1.7%	-$6.8M+39.1%	-$11.2M+6.4%	-$11.9M-56.5%	-$7.6M
Capital Expenditures	N/A	N/A	N/A	N/A	$65K	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	-$12.0M	N/A
Investing Cash Flow	$150K	N/A	$1.5M	N/A	-$34K+90.3%	-$350K
Financing Cash Flow	$8.5M+8.0%	$7.8M+89.9%	$4.1M-54.7%	$9.1M-33.1%	$13.6M+143.3%	$5.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$2K	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$1.3M+27.8%	-$1.8M-4.8%	-$1.7M-10.3%	-$1.6M-9.1%	-$1.5M+14.2%	-$1.7M+21.1%	-$2.1M-32.1%	-$1.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	$0-100.0%	$150K	N/A	N/A	N/A	N/A
Financing Cash Flow	$2.6M+395.4%	$525K-90.1%	$5.3M+10361.4%	$51K	$0-100.0%	$3.6M+778.2%	$411K-89.3%	$3.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ADIL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-151.2%+173.2pp	-324.4%-199.0pp	-125.5%+263.1pp	-388.6%+165.2pp	-553.7%-280.4pp	-273.3%
Return on Assets	-119.5%+142.1pp	-261.6%-153.5pp	-108.2%+113.9pp	-222.1%+37.8pp	-259.8%-61.5pp	-198.4%
Current Ratio	4.42+0.3	4.16-0.7	4.90+2.2	2.67+0.3	2.37-1.0	3.41
Debt-to-Equity	0.26+0.0	0.24+0.1	0.16-0.6	0.75-0.4	1.13+0.8	0.38
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-39.8%-4.8pp	-35.0%+69.8pp	-104.8%	N/A	-37.3%+20.2pp	-57.5%+48.3pp	-105.8%
Return on Assets	N/A	-31.7%-2.9pp	-28.8%+35.8pp	-64.6%	N/A	-32.6%+17.0pp	-49.7%	N/A
Current Ratio	4.42+0.1	4.34-0.7	5.02+3.0	1.99-2.2	4.16-2.6	6.78+1.1	5.69	N/A
Debt-to-Equity	0.260.0	0.26+0.0	0.22-0.4	0.62+0.4	0.24+0.1	0.14-0.0	0.16	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Alzamend Neuro Inc ALZN

$3.9M

Vyne Therapeutics Inc VYNE

$20.2M

Brainstorm Cell Therapeutics I BCLI

$12.0M

TNF Pharmaceuticals TNFA

$9.6M

Creative Med Technology Hldgs CELZ

$7.4M

Frequently Asked Questions

Is Adial Pharmaceuticals Inc profitable?

No, Adial Pharmaceuticals Inc (ADIL) reported a net income of -$8.0M in fiscal year 2025.

What is Adial Pharmaceuticals Inc's return on equity (ROE)?

Adial Pharmaceuticals Inc (ADIL) has a return on equity of -151.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Adial Pharmaceuticals Inc's operating cash flow?

Adial Pharmaceuticals Inc (ADIL) generated -$6.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Adial Pharmaceuticals Inc's total assets?

Adial Pharmaceuticals Inc (ADIL) had $6.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Adial Pharmaceuticals Inc spend on research and development?

Adial Pharmaceuticals Inc (ADIL) invested $2.6M in research and development during fiscal year 2025.

How many shares does Adial Pharmaceuticals Inc have outstanding?

Adial Pharmaceuticals Inc (ADIL) had 1M shares outstanding as of fiscal year 2025.

What is Adial Pharmaceuticals Inc's current ratio?

Adial Pharmaceuticals Inc (ADIL) had a current ratio of 4.42 as of fiscal year 2025, which is generally considered healthy.

What is Adial Pharmaceuticals Inc's debt-to-equity ratio?

Adial Pharmaceuticals Inc (ADIL) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Adial Pharmaceuticals Inc's return on assets (ROA)?

Adial Pharmaceuticals Inc (ADIL) had a return on assets of -119.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Adial Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Adial Pharmaceuticals Inc (ADIL) had $5.9M in cash against an annual operating cash burn of $6.5M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Adial Pharmaceuticals Inc's Piotroski F-Score?

Adial Pharmaceuticals Inc (ADIL) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Adial Pharmaceuticals Inc's earnings high quality?

Adial Pharmaceuticals Inc (ADIL) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.